VETIVEX 11 solution for infusion for cattle, horses, dogs and cats

Main information

  • Trade name:
  • Vetivex 11
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Vetivex 11
    Germany
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • electrolytes
  • Therapeutic area:
  • Cats, Cattle, Cattle Young, Dogs, Horses

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0458/001
  • Authorization date:
  • 24-04-2013
  • EU code:
  • UK/V/0458/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:June2013

AN:00149/2012

Page1of5

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

VETIVEX11solutionforinfusionforcattle,horses,dogsandcats[UK,IE]

VETIVEXRingerLactateSolutionforinfusionforcattle,horses,dogsandcats[BE,FR,

NL]

INFUSOLECsolutionforinfusionforcattle,horses,dogsandcats[DE,DK,SE]

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

1mlcontains:

Activesubstances:

SodiumLactate 3.17mg

SodiumChloride 6.00mg

PotassiumChloride 0.40mg

CalciumChloride 0.20mg

(equivalenttoCalciumChlorideDihydrate:0.27mg)

Sodium:131mmol/litre

Potassium:5mmol/litre

Calcium:2mmol/litre

Bicarbonate(aslactate):29mmol/litre

Chloride:111mmol/litre

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Solutionforinfusion.

Clear,colourlesssolution.

4. CLINICALPARTICULARS

4.1Targetspecies

Cattle,horses,dogsandcats.

4.2Indicationsforuse,specifyingthetargetspecies

Thisproductisadministeredbyintravenousinfusionforthetreatmentofdehydrationand

metabolicacidosisincattle,horses,dogsandcats.Itmaybeusedtocorrectvolume

depletion(hypovolaemia)resultingfromgastrointestinaldiseaseorshock.

4.3Contraindications

Lactate-containingsolutionswillnotbeutilisedeffectivelyinanimalswithhepatic

impairmentanditisundesirabletousethisproductinanimalswithmetabolicalkalosis.

Issued:June2013

AN:00149/2012

Page2of5

4.4Specialwarningsforeachtargetspecies

None.

4.5Specialprecautionsforuse

Specialprecautionsforuseinanimals:

Donotuseunlessthesolutionisclear,freefromvisibleparticles,andthecontaineris

undamaged.

Ariskofthrombosiswithintravenousinfusionshouldbeconsidered.

Maintainasepticprecautions.

Thisproductshouldbewarmedtoapproximately37 o

Cpriortotheadministrationof

largevolumes,oriftheadministrationrateishigh,inordertoavoidhypothermia.

Donotuseunlessthesolutionisclear,freefromvisibleparticles,andthecontaineris

undamaged.

Thisproductdoesnotcontainanantimicrobialpreservative.Itisintendedforsingleuse

onlyandanyunusedcontentsshouldbediscarded.

Thisproductshouldbeusedwithcautioninanimalswithcardiacorrenalimpairmentas

sodiumoverloadmayoccur.

Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinal

producttoanimals:

None.

4.6Adversereactions(frequencyandseriousness)

Excessiveinfusionratescancauserestlessness,moistlungsounds,tachycardia,

tachypnoea,nasaldischarge,coughing,vomitinganddiarrhoea.

4.7Useduringpregnancy,lactationorlay

Useunderveterinarysupervision.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Thisproductisincompatiblewithmethylprednisolone,andsodiumlactateorsodium

bicarbonateintravenousinfusions.

4.9Amountstobeadministeredandadministrationroute

Intravenoususe.

Theinfusionshouldideallybewarmedtoapproximately37 o Cpriortoadministration.

Thevolumeandrateofinfusionwilldependupontheclinicalcondition,existingdeficits

oftheanimal,maintenanceneedsandcontinuinglosses.

Generallyaimtocorrecthypovolaemiaby50%initially(ideallyover6hoursbutfasterif

necessary)andreassessbyclinicalexamination.

Deficitsaregenerallyintherangeof50ml/kg(mild)to150ml/kg(severe).Aninfusion

rateof15ml/kg/hourisrecommendedintheabsenceofshock(range5-75ml/kg/hour).

Issued:June2013

AN:00149/2012

Page3of5

Inshock,highinitialinfusionrates,upto90ml/kg/hour,areneeded.Highinfusionrates

shouldnotbecontinuedforlongerthan1hourunlessrenalfunctionandurineoutputare

restored.Themaximuminfusionrateshouldbedecreasedinthepresenceofcardiac,

renalandpulmonarydisease.

4.10Overdose(symptoms,emergencyprocedures,antidotes)

Monitorfluidoutput.

4.11Withdrawalperiods

Cattleandhorses:Meatandoffal/milk –zerodays/hours.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Electrolytes, ATCvetcode:QB05BB01

5.1Pharmacodynamicproperties

Thisproductreplacesdepletedwaterandelectrolyteswhenadministeredviathe

intravenousroute,tocorrectwaterimbalanceindehydration,andrestoreelectrolyteand

acid-basebalance.Itwillrestoreplasmavolumeandcorrectmetabolicacidosis,asthe

hepaticmetabolismoflactateyieldsbicarbonateslowlyenoughtopreventacounter-

imbalanceofalkalosis.

5.2Pharmacokineticparticulars

Intravenousinfusionensuresrapiddistribution.Theconstituentsoftheinfusionsolution

willbemetabolisedandexcretedthroughthesamepathwaysasthosesubstances

derivedfromnormaldietarysources.

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Waterforinjections

Hydrochloricacid,dilute(forpH-adjustment)

6.2Incompatibilities

Thisproductisincompatiblewithmethylprednisolone,andsodiumlactateorsodium

bicarbonateintravenousinfusions.

6.3Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:18months

Theproductshouldbeusedimmediatelyandnotstoredafteropening.

Issued:June2013

AN:00149/2012

Page4of5

6.4.Specialprecautionsforstorage

Donotstoreabove25

C.

Donotfreeze.

6.5Natureandcompositionofimmediatepackaging

Polyvinylchlorideinfusionbagsoverwrappedwithpolypropylene.

Allpacksizeshavetwoports.Inplaceoftheadditiveportonthe5000mlcombipackis

acombiport.Thisenablestwosuchbagstobeconnectedinsequenceandvolumes

greaterthan5000mltobeadministeredduringoneinfusion.

Packsizes:250ml,500ml,1000ml,3000ml,5000mland5000mlcombi.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchmedicinal

productsshouldbedisposedofinaccordancewithlocalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

DechraLimited

DechraHouse

JamageIndustrialEstate

TalkePits

Stoke-on-Trent

Staffordshire

ST71XW

UK

8. MARKETINGAUTHORISATIONNUMBER

Vm10434/4080

9. DATEOFFIRSTAUTHORISATION

20June2013

10.DATEOFREVISIONOFTHETEXT

June2013

Issued:June2013

AN:00149/2012

Page5of5

Approved: 20/06/2013

21-11-2018

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9% Due to Product Labeling Incorrectly Stating Stoppers Do Not Contain Latex

Fresenius Kabi USA is voluntarily recalling 163 lots of Sodium Chloride Injection, USP, 0.9%, 10 mL fill in a 10 mL vial and Sodium Chloride Injection, USP, 0.9%, 20 mL fill in a 20 mL vial to the user level. The product insert states that stoppers for both the 10mL and the 20mL vials do not contain natural rubber latex; the tray label for the two vial sizes and the vial label for the 20mL vial also state that the stoppers do not contain latex. The product is being recalled because the stoppers contain n...

FDA - U.S. Food and Drug Administration

7-9-2018

SCA Pharmaceuticals LLC. Issues Voluntary Nationwide Recall of Furosemide 100 mg in 0.9% Sodium Chloride due to Presence of Precipitate

SCA Pharmaceuticals LLC. Issues Voluntary Nationwide Recall of Furosemide 100 mg in 0.9% Sodium Chloride due to Presence of Precipitate

, SCA Pharmaceuticals LLC (“SCA Pharma”) is voluntarily recalling 7 lots of the injectable product Furosemide 100 mg in 0.9% Sodium Chloride 100 mg bag to the consumer level. This product is being recalled for visible particulate matter believed to be furosemide precipitate.

FDA - U.S. Food and Drug Administration

There are no news related to this product.